Oligodendroglioma historical perspective
|
Oligodendroglioma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Oligodendroglioma historical perspective On the Web |
|
American Roentgen Ray Society Images of Oligodendroglioma historical perspective |
|
Risk calculators and risk factors for Oligodendroglioma historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2]Sujit Routray, M.D. [3]
Overview
In 1926, the term "oligodendroglioma" was first coined by Bailey and Cushing, and was first described and published by W. E. Carnegie Dickson. Oligodendrogliomas were first classified and graded in a system devised by Bailey and Cushing, and later revised by Kernohan, Ringertz, and others, and since then, classification and grading of gliomas have evolved over the time. Modern WHO classification of oligodendrogliomas was first published in 1979 and revised four times since then, with the most recent published in 2016. In 1997, a Westergaard's study showed that patients younger than 20 years had a median survival of 17.5 years. In 2001, a study at Mayo Clinic was conducted to assess the prognostic value of histological grading of oligodendroglial tumors in tumor grading and significant association with survival was found for age, high cellularity, presence of mitoses, endothelial hypertrophy and proliferation and necrosis on univariateanalysis, but only age and presence of endothelial proliferation were found to be independently associated with survival on a multivariable analysis. In 2009, NJDSmutation was first identified in the pathogenesis of oligodendroglioma by Kevin Smith. It was suggested in 2009 ASCO Annual Meeting that PCV therapy may be superior in efficacy to the newer temozolomide therapy. Irradiation of pituitary adenoma was also discovered to be associated with oligodendroglioma by Kevin Smith et al.
Historical Perspective
- The term oligodendroglioma was derived from the Greek words "oligo" meaning few and "dendro" meaning trees.
- In 1926, the term "oligodendroglioma" was first coined by Bailey and Cushing following the observation that the tumor cells are morphologically similar to oligodendrocytes.[1]
- In 1926, oligodendroglioma was first described and published by W. E. Carnegie Dickson.[2]
- In 1926, oligodendrogliomas were first classified and graded in a system devised by Bailey and Cushing, and later revised by Kernohan, Ringertz, and others, and since then, classification and grading of gliomas have evolved over the time.
- In 1979, modern classification of gliomas based on the World Health Organization (WHO) Classification of Central Nervous System Tumors was first published and revised four times since then.
- In 1997, a Westergaard's study showed that patients younger than 20 years had a median survival of 17.5 years.[3]
- In March 2001, 7 neuropathologists and 6 surgical pathologists experienced in brain tumor-diagnosis assessed 124 oligodendroglial tumors operated at the Mayo Clinic during the period of 1960 to 1990. In this study, the prognostic value of histological grading of oligodendroglial tumors in tumor grading was assessed, and significant association with survival was found for age, high cellularity, presence of mitoses, endothelial hypertrophy and proliferation and necrosis on univariate analysis. However, only age and presence of endothelial proliferation were found to be independently associated with survival on a multivariable analysis.[4]
- In 2009 Oxford Neurosymposium study by Kevin Smith, it was first discovered that there is a 69% correlation between NJDS gene mutation and oligodendroglial tumor initiation.[5]
- In 2009 ASCO Annual Meeting, it was suggested that PCV therapy may be superior in efficacy to the newer temozolomide therapy. This study showed that median time to progression for patients with 1p19q co-deletion is longer following PCV alone (7.6 years) than with temozolomide alone (3.3 years); median overall survival is also longer with PCV treatment versus temozolomide treatment (not reached, vs. 7.1 years).[6]
- Kevin Smith et al also discovered that irradiation of pituitary adenoma is associated with precipitation of oligodendroglioma.
- In 2016 edition of the most recent WHO classification, gliomas are classified based not only on histopathologic appearance but also on well-established molecular parameters.
References
- ↑ Hartmann C, von Deimling A (2009). "Molecular pathology of oligodendroglial tumors". Recent Results Cancer Res. 171: 25–49. doi:10.1007/978-3-540-31206-2_2. PMID 19322536.
- ↑ Dickson, WEC (1926), Proceeding of the Section of Neurology of the Royal Society Medicine: Oligodendroglioma of Floor of Third Ventricle, Brain-A journal of neurology, p. 578, retrieved 11/20/2015 Check date values in:
|accessdate=(help) - ↑ Engelhard, Herbert H; Stelea, Ana; Mundt, Arno (2003). "Oligodendroglioma and anaplastic oligodendroglioma:". Surgical Neurology. 60 (5): 443–456. doi:10.1016/S0090-3019(03)00167-8. ISSN 0090-3019.
- ↑ Giannini C, Scheithauer BW, Weaver AL, Burger PC, Kros JM, Mork S; et al. (2001). "Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading". J Neuropathol Exp Neurol. 60 (3): 248–62. PMID 11245209.
- ↑ Etiology of oligodendroglioma. Wikipedia. https://en.wikipedia.org/wiki/Oligodendroglioma
- ↑ . doi:10.1200/jco.2009.27.15s.2014. Missing or empty
|title=(help)